Burning Rock Biotech Ltd. (BNR) - Margin reged

Simbol resmi perusahaan Burning Rock Biotech Ltd. (BNR)

Burning Rock Biotech (BNR) is overcoming the market downturn in China by optimizing expenses amid pricing wars. The gross margin clearly demonstrates the long-term development vector, with the latest value recorded as 74.50. This NGS diagnostics leader is investing in AI-driven blood analysis. Simultaneously, Burning Rock Biotech (BNR) is implementing eco-friendly bio-waste disposal standards, reducing laboratory energy consumption to protect the environment.

BNR (Burning Rock Biotech Limited) riwayat Rentabilitas reged saka 04.07.2022 nganti 20.11.2026

Rincian analitis lan laporan data perusahaan Burning Rock (BNR)

- rega saham lan konsensus proyeksi valuasi:
Produk seri brbiotech.com

Burning Rock Biotech operates under severe pricing pressure and dependence on Chinese oncology diagnostics regulations. The current value of 74.50 reflects the revenue share minus direct production costs, allowing for an assessment of cost management efficiency amid a shortage of Western reagents, while the gross margin trend visualizes the business model's resilience to external risks.